No Data
Jingfeng Pharmaceutical's Unit Gets Registration Certificate for Montelukast Sodium Chewable Tablets
*ST Jingfeng (000908.SZ): The subsidiary has received the Pharmaceutical registration certificate for Montelukast Sodium Chewable Tablets.
On February 10, 2023, *ST Jingfeng (000908.SZ) announced that recently, Hunan Jingfeng Pharmaceutical Co., Ltd.'s subsidiary Hainan Jinrui Pharmaceutical Co., Ltd. received the Drug Registration Certificate issued by the National Medical Products Administration for the Chemical Drug "Montelukast Sodium Chewable Tablets." Montelukast Sodium is a highly selective and potent leukotriene receptor antagonist that blocks the interaction between cysteinyl leukotrienes and receptors, thereby blocking the organ's response to leukotrienes, achieving the goal of controlling asthma. It is significantly effective in treating asthma and is suitable for the prevention and long-term treatment of asthma in children aged 2 to 14.
*ST Jingfeng: 2024 performance forecast
*Special Treat Jingfeng (000908.SZ): Expected profit for the year 2024 is between 0.11 billion yuan and -0.16 billion yuan.
*ST Jingfeng (000908.SZ) announced its performance forecast for 2024 on January 21. The total profit for 2024 is expected to be between 0.12 billion yuan and 0.16 billion yuan; the net income attributable to shareholders of the listed company is expected to be between 0.11 billion yuan and 0.16 billion yuan, turning from loss to profit year-on-year; the net income after deducting non-recurring gains and losses is expected to be a loss of between 68 million yuan and 100 million yuan; the basic EPS is expected to be between 0.13 yuan/share and 0.18 yuan/share; the revenue is expected to be between 0.38 billion yuan and 0.42 billion yuan, and the operating revenue after deductions is expected to be between 0.38 billion yuan and 0.42 billion yuan. During the reporting period, the company and
*ST Jingfeng (000908.SZ): The main business currently has no other significant changes. Trading will resume on November 21.
On November 20, Gelonghui reported that *ST Jingfeng (000908.SZ) announced that according to the relevant regulations including the "Guidelines for Self-Discipline Supervision for Listed Companies No. 6 - Suspension and Resumption of Trading" issued by the Shenzhen Stock Exchange, upon the company's application, the company's stocks (abbreviated as *ST Jingfeng, stock code: 000908) will resume trading starting on November 21, 2024 (Thursday). The company's stock price has increased by 752.78% from July 3, 2024, to November 15, 2024, with significant price fluctuations. The company reminds all investors to pay attention to the trading risks in the secondary market. After consulting with the company management and controlling shareholder.
*Special treat Jingfeng (000908.SZ): Suspended for verification from the market opening on November 18th.
On November 17, 2023, *ST Jingfeng (000908.SZ) announced that the price increase of its stocks from July 3, 2024, to November 15, 2024, was 752.78%. The stock price has been quite volatile, drawing considerable attention from investors. To protect the interests of investors, the company will investigate the fluctuations in stock trading. Upon the company's application, trading of the stocks will be suspended starting November 18, 2024, until the investigation concludes and the relevant announcement is disclosed, with the suspension expected to last no more than three trading days. Verification has been conducted with the company's management, controlling shareholders, and actual controllers.
Even After Rising 19% This Past Week, Hunan Jingfeng PharmaceuticalLtd (SZSE:000908) Shareholders Are Still Down 49% Over the Past Five Years
